Evolus Inc

For the period ended Dec 31, 2024. Filed Mar 4, 2025.

About this filing

A company's yearly report to the SEC, with audited financial statements. It is the fullest account a company gives of its business, its finances and the risks it sees.

FY2024 · Filed Mar 4, 2025

EOLS$6.81-2.4%Stored close · as of Nov 10, 2026

Extracted filing text, with the paragraph anchors used by the comparison.

See the whole filing, with its images and exhibits

Contents

Consolidated Statements of Operations and Comprehensive Loss

	Year Ended December 31,
	2024	2023	2022
Revenue:
Product revenue, net	$264,306	$199,721	$146,592
Service revenue	1,968	2,364	2,024
Total net revenues	266,274	202,085	148,616
Cost of goods sold	83,970	64,514	58,842
Gross profit	182,304	137,571	89,774
Operating expenses:
Selling, general and administrative	198,025	164,944	141,840
Research and development	9,172	6,556	4,742
In-process research and development	—	8,869	2,000
Revaluation of contingent royalty obligation payable to Evolus Founders	7,176	4,257	5,755
Depreciation and amortization	2,342	2,178	767
Total operating expenses	216,715	186,804	155,104
Loss from operations	(34,411)	(49,233)	(65,330)
Other income (expense):
Interest income	3,263	860	119
Interest expense	(18,735)	(13,832)	(9,097)
Other income (expense), net	127	696	(9)
Loss before income taxes:	(49,756)	(61,509)	(74,317)
Income tax expense	664	176	95
Net loss	$(50,420)	$(61,685)	$(74,412)
Other comprehensive loss:
Unrealized loss, net of tax	(478)	(90)	(337)
Comprehensive loss	$(50,898)	$(61,775)	$(74,749)
Net loss per share, basic and diluted	$(0.81)	$(1.08)	$(1.33)
Weighted-average shares outstanding used to compute basic and diluted net loss per share	62,016,853	56,918,721	56,065,297

ContentsView on SEC.gov

The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.